• Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Unspecified (PubMed=23489693).
  

PubMed=2174414; DOI=10.1002/ijc.2910460629
Deschodt-Lanckman M.M., Vanneste Y., Loir B., Michel A., Libert A., Ghanem G., Lejeune F.
Degradation of alpha-melanocyte stimulating hormone (alpha-MSH) by CALLA/endopeptidase 24.11 expressed by human melanoma cells in culture.
Int. J. Cancer 46:1124-1130(1990)

PubMed=23489693
Zanna P., Maida I., Grieco C., Guida S., Turpin Sevilla M.C., De Summa S., Tommasi S., Vena G.A., Filotico R., Guida G.
Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and beta-catenins.
J. Biol. Regul. Homeost. Agents 27:131-141(2013)

PubMed=25623468; DOI=10.1186/s12967-015-0385-4; PMCID=PMC4314759
Porcelli L., Guida G., Quatrale A.E., Cocco T., Sidella L., Maida I., Iacobazzi R.M., Ferretta A., Stolfa D.A., Strippoli S., Guida S., Tommasi S., Guida M., Azzariti A.
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
J. Transl. Med. 13:26.1-26.13(2015)

PubMed=27540956; DOI=10.1111/pcmr.12516
Guida M., Strippoli S., Ferretta A., Bartolomeo N., Porcelli L., Maida I., Azzariti A., Tommasi S., Grieco C., Guida S., Albano A., Lorusso V., Guida G.
Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors.
Pigment Cell Melanoma Res. 29:679-687(2016)